



**Resonance Health Ltd**  
**ASX / Media Release**

**3 September 2014**

---

## **Resonance Health joins Forum on Facilitating Drug Development for the Treatment of Liver Disease**

Resonance Health is delighted to be invited to join the Forum on Facilitating Drug Development for the Treatment of Liver Disease. The Forum provides the opportunity for key opinion leaders and stakeholders to work together in the development of safe and effective therapies and diagnostic tools to treat liver fibrosis and cirrhosis.

Non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B (HBV), and chronic hepatitis C infection are the leading causes of chronic liver disease and hepatocellular carcinoma in the United States. NAFLD is associated with the development of type 2 diabetes and cardiovascular disease. NAFLD related liver transplantations are predicted to eclipse other indications over the next decade and is a dominant cause of hepatocellular carcinoma (HCC), the only cancer with rising incidence and third leading cause of cancer mortality.

As a result of the growing healthcare issues associated with liver disease, this Forum has been established to provide a venue for ongoing multi-stakeholder dialogue with the aim of advancing the treatment of liver disease. Stakeholders include the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), specialist physicians, academics, patient communities and major pharmaceutical companies.

Resonance Health is pleased to be in a position to participate in this Forum as a medical device company focused on developing non-invasive diagnostic tools specifically aimed at liver disease including the assessment of iron overload, fatty liver disease and liver fibrosis.

Information about the Forum can be found at this link.

<http://www.hivforum.org/projects/drug-development/168-fibrosis/1085-nash-fibrosis>

For further information please contact:

**Resonance Health**

Adrian Bowers  
Company Secretary  
T: +61 8 9286 5300  
E: [adrianb@resonancehealth.com](mailto:adrianb@resonancehealth.com)

Liza Dunne  
Managing Director  
T: +61 8 9286 5300  
E: [lizad@resonancehealth.com](mailto:lizad@resonancehealth.com)

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing imaging core laboratory services for the quantitative analysis of MR medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.